Thursday, January 14, 2010
Note: advances in the imaging of ovarian cancer
Surgery duration linked to infectious complications, hospital stay - Anesthesiology Videos - The Doctor's Channel
not specific to ovarian cancer
Note: this was posted in November, but I have brought the posting date forward to coincide with other like articles, so both can be viewed at the same time. Access to this article requires that you sign on to the website (free).
Targeted Therapy in Ovarian Cancer
Lyndsay J. Willmott and John P. Fruehauf
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA Academic Editor: Charles F. Levenback
Defective Mismatch Repair, Microsatellite Mutation Bias, and Variability in Clinical Cancer Phenotypes -- Shah et al. 70 (2): 431 -- Cancer Research
"Microsatellite instability is associated with 10% to 15% of colorectal, endometrial, OVARIAN, and gastric cancers, and has long been used as a diagnostic tool for hereditary nonpolyposis colorectal carcinoma–related cancers. Tumor-specific length alterations within microsatellites are generally accepted to be a consequence of strand slippage events during DNA replication, which are uncorrected due to a defective postreplication mismatch repair (MMR) system. Mutations arising within microsatellites associated with critical target genes are believed to play a causative role in the evolution of MMR-defective tumors. In this review, we summarize current evidence of mutational biases within microsatellites arising as a consequence of intrinsic DNA sequence effects as well as variation in MMR efficiency. Microsatellite mutational biases are generally not considered during clinical testing; however, we suggest that such biases may be clinically significant as a factor contributing to phenotypic variation among microsatellite instability–positive tumors."
Comment: Before Erythropoiesis-stimulating agents were introduced, blood transfusions were widely used for the improvement of platelet counts etc. With recent negative research regarding Erythropoiesis-stimulating agents, blood transfusions will be a choice - seek professional/oncologist opinion. This article from the ACS describes some of the concerns with blood transfusions.
Phase III Randomized Study of Glutathione for the Prevention of Paclitaxel/Carboplatin-Induced Peripheral Neuropathy in Patients With Ovarian, Fallopi
Phase III Randomized Study of Glutathione for the Prevention of Paclitaxel/Carboplatin-Induced Peripheral Neuropathy in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Carcinoma
What are interleukins?
"Like interferons, interleukins (ILs) are cytokines that occur naturally in the body and can be made in the laboratory. Many interleukins have been identified; interleukin-2 (IL–2 or aldesleukin) has been the most widely studied in cancer treatment. IL–2 stimulates the growth and activity of many immune cells, such as lymphocytes, that can destroy cancer cells. The FDA has approved IL–2 for the treatment of metastatic kidney cancer and metastatic melanoma.
Researchers continue to study the benefits of interleukins to treat a number of other cancers, including leukemia, lymphoma, and brain, colorectal, ovarian, breast, and prostate cancers."
Wednesday, January 13, 2010
Molecular Cancer | Full text | Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas
CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
Conclusions: "Our ROC analysis did not demonstrate any reliable CA-125 cutoff on response. Discontinuation of the therapy before cycle 3 may exclude some patients who will benefit from PLD."
"CAN you name the six basic emotions? Take a straw poll of your friends and we guarantee that you will find no consensus. Yet psychologists are unequivocal: joy, sadness, anger, fear, surprise and disgust...."
media item: new anti-cancer drug called "COTI-2" TD2 and Critical Outcome Technologies Inc. Develop Novel Anti-Cancer Drug
"....small molecule compound was discovered and developed by COTI of London, Ontario, Canada. This working relationship resulted through the expanded relationship between Canadian companies and the Phoenix-based Translational Genomics Research Institute (TGen). TD2, TGen's Scottsdale-based drug-development subsidiary, will work with COTI to complete the Investigational New Drug (IND) enabling research necessary to gain U.S. Food and Drug Administration approval of clinical trials,perhaps by the end of 2010, and eventually move the drug to market where it can benefit patients.....Researchers hope to demonstrate that this oral pill will be especially beneficial for patients with small- cell lung cancer (SCLC), endometrial cancer and ovarian cancer, but may also help treat those with colorectal and pancreatic cancers."
Beyond the history, at the bottom of the page, there are a number of links which you may find interesting such as:
* 100 Best Blogs for Living Healthy on a Budget
* The Surgery is Over… Now What? 4 Tips for A Successful Rehab
* Top 100 Doctor Bloggers
* 100+ Ways to Spring Clean Your Mind and Body
* The Top 50 Surgeon Bloggers
* What Does a Surgical Technician Do?
full free access: Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives
Small study but included view of patients and physician views.
Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study
"Our findings offer evidence of differences in the hormone-related risk factors between triple-negative cancers and other ER/PR/HER2-defined subtypes of breast cancer."
Collaborating or co-existing: a survey of attitudes of medical oncologists toward specialist palliative care
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
"Twelve patients entered the study, and accrual was terminated in the first stage because of lack of response or disease stabilization beyond 6 months."
NCI Cancer Bulletin: PARP Inhibitor and Metronomic Chemotherapy for Refractory Cancer - Phase I Study of ABT-888 and Metronomic Cyclophosphamide ....
Name of the Trial:
Phase I Study of ABT-888 and Metronomic Cyclophosphamide in Patients with Refractory Solid Tumors or Lymphoma (NCI-09-C-0048).
For More Information (read the article to see direct links to the information):
See the lists of eligibility criteria and trial contact information or call the NCI Clinical Trials Referral Office at 1-888-NCI-1937. The call is toll free and confidential.
Tuesday, January 12, 2010
"New research by Samir Hanash, Ross Prentice and colleagues, recently published in Genome Medicine, suggests that the different proteomic effects of estrogen-alone and estrogen plus progestin treatments may explain the distinctive clinical effects of each therapy."
UC Academic Health News : Findings: UC Gynecologic Cancer Team Expands Services to Northern Kentuck-Dayton
"His goal is to recruit three additional double board-certified gynecologic oncologists who are qualified to perform both cancer care as well as advanced pelvic surgery. This team will cover a wide range east and west of the I-75 stretch between Northern Kentucky and Dayton."
abstract: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes
definitions we need to know when reading this abstract:
1) microenvironment: a specific set of physical, biological, and chemical factors immediately surrounding the organism;
2) epigenetic: - something that affects a cell, organ or individual without directly affecting its DNA.
"Conclusions: The rates of optimal cytoreduction vary among surgeons. A universally applicable clinical model that can predict which patients will undergo optimal cytoreduction remains elusive. More research is needed to devise a set of uniform criteria that can be used to predict ovarian cancer resectability among different patient populations."
June 17-19, 2010
Marriott Wardman Park Hotel
The Biennial Cancer Survivorship Research Conference, initiated in 2002 by the National Cancer Institute’s Office of Cancer Survivorship and the American Cancer Society’s Behavioral Research Center, brings together investigators, clinicians, and survivors to share and learn about the most up-to-date cancer survivorship research. In 2010, the 5th biennial conference is co-sponsored by the National Cancer Institute, the American Cancer Society, LIVESTRONG, and the Centers for Disease Control and Prevention.
press release: Nektar Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer
"The first stage of the NKTR-102 Phase 2 study showed an overall GCIG response rate of 32% (6/19) in the once every 14 days (q14 day) dose schedule and 35% (7/20) for the once every 21 days (q21 day) dose schedule.
Confirmed objective response rates using RECIST were 21% (4/19) and 22% (4/18) for the q14 day and q21 day dose schedules, respectively.
CA-125 response rates were 31% (5/16) and 38% (6/16), for each dose schedule, respectively.
The Phase 2 study has now completed enrollment with a total of 71 patients. Approximately one-third of the patients in the study remain on NKTR-102 treatment, including a number of patients in the first stage of the study."
abstract: Generational risks for cancers not related to tobacco, screening, or treatment in the United States
Despite declining overall cancer death rates, adults are experiencing increased incidence of cancers that are not associated with tobacco or screening relative to their parents. Future research should examine whether similar patterns are exhibited in other modern nations and should identify population-wide avoidable risks that could account for unexplained increases in these residual cancers."
this link is the actual research article and from which the media item was based (abstract/only-pay-per-view)
My response, assuming it gets posted:
"As a cancer (ovarian) survivour, the value of the research and 'weight' concerns are ever present. However, at this very moment weight issues in cancer are primarily a health issue with many unknowns as it relates to specific implications in specific cancers. I see many websites/programs who arbitrarily have included 'weight' issues as a risk factor. Until the exact mechanisms and results are known, I urge great caution as this adds to significant burdens on patients who at this very moment are fighting to survive. It is not ethically or morally appropriate to add to these burdens for those dying of cancer."
It should be emphasized that the FDA release focuses solely on patients with chronic renal disease, not cancer. It's a different population, so nothing in this release applies to the anemia of chemotherapy or patients with myelodysplastic syndrome. Right now, the ASCO/ASH ESA guideline committee is looking at present data to see if they need to make any modifications in the guidelines for the use of ESAs. The NCCN modified its guideline about a year ago and agree with the FDA recommendations that ESAs shouldn't be used in a standard fashion in patients being treated for curative intent. That's become standard of care, and for patients on chemotherapy, nothing has changed in the past year.
- Samuel Silver, MD, PhD
HemOnc Today Editorial Board member"
Special Report: NCI Cancer Bulletin - Ovarian Cancer
Depression assessment and classification in palliative cancer patients: a systematic literature review
"The full range of the DSM-IV diagnostic criteria was seldom assessed,i.e. less than one-third of the assessments in the review tookinto account the duration of symptoms and 18% assessed consequences and impact upon patient functioning. A diversity of assessment methods had been used. Few studies classified depression byreferring to a diagnostic system or by using cut-off scores.Evidently, there is a need for a consensus on how to assessand conceptualize depression and related conditions in palliative care."
Monday, January 11, 2010
Paraneoplastic neurologic disorders occur in some people with cancer—including lung, breast or ovarian cancer
Letter of Response: Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement
Dear Dr Sprangers;
I want to express my appreciation for your paper detailing these Patient and research issues which have been outstanding and often unheeded far too long. Unfortunately, I must add, even as we speak. These issues have been of great concern to our cancer communities over much time. Without the inclusion of Patients in all that affects the research, at and as the bottom line issue, the value and efforts are, yes, meaningless. Patient QOL measurements, need to be addressed, so that the real life issues are not censured through statistical analyses and re-interpretation.
Without an emphasis encompassing integrity and ethics, if not a moral obligation, QOL research and all research, is futile. It is one of our largest failings. I have never found a way to quite understand how we have gotten to this place, not only in research but often times in practice.
I do see glimmers of hope, but over time these 'glimmers' have been replaced with consistently witnessing, as a patient/survivour, much suffering combined with a profess lack of urgency. While understanding of course that the specific issue of Patient QOL does not operate in a silo, it is because we are.
Acknowledging special exceptions in clinical practice/s, when someone mentions: "I know how you feel" my response is quite simply this: "No, actually, you do not."
Thank you once again, I greatly appreciate your efforts.
Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life
"Background. The clinical impact of trial-based quality of life (QL) outcomes is frequently underestimated due, in part, to prejudice and lack of knowledge by the medical community ....It is a waste of effort and money and also unethical when collected trial-based QL data are not used to their full power. QL and other patient-reported outcomes deserve to be included in more trials, with full disclosure of all results, and standardized interpretation."
Sunday, January 10, 2010
abstract for our Lynch Syndrome/ovarian members or also those who family members may have been diagnosed with advanced colorectal cancer
2009 University of Health Network Toronto Patient Relations report - Office of the (hospital) Ombudsman
This report is of questionable value to patients as the Office of the Ombudsman is not independent but within the institution.
"The Patient Relations Department (Office of the Hospital Ombudsman)"
(repost): Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity : BMJ
abstract only - BMJ does not have open access (pay per view/subscription req'd)
Saturday, January 09, 2010
"Participants were stratified by risk level and included those concerned about an inherited predisposition to breast, ovarian or colorectal cancer."
"Findings indicated that irrespective of a person's actual or perceived level of risk, cancer worry, demographic background or personal motivation; priorities in the type of information required were similar. Greatest emphasis focused on information provision about how risk was assessed. Least important was acquiring an understanding about genes and inheritance patterns. Most participants reported difficulties accessing or finding information."
"Many patients reporting a known familial cancer syndrome or a very strong family history did not have that history indicated on the endoscopist's procedure form, and recommended follow-up intervals were beyond guideline recommendations for 60.4% of the very high-risk group."
plus commentaries from oncologists
abstract: Using More End-of-Life Homecare Services is Associated With Using Fewer Acute Care Services: A Population-Based Cohort Study.
Note: look at the hours
Occult fallopian tube carcinoma detected in routine pelvic washing specimens submitted for staging: another justification for pelvic washing cytology?
Diagn Cytopathol. 2009 Dec;
Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA. firstname.lastname@example.org
"Peritoneal washing cytology is important in the staging, prognosis, and treatment schema for women diagnosed with gynecologic malignancies. Additionally, peritoneal washings are often performed before the specific diagnosis or even the distinction between benign or malignant lesion is known. Occasionally, the cytology and surgical pathology specimens, although obtained during the same procedure, will show unexpected and/or discordant findings. Perhaps, the greatest dilemma occurs when atypical cells suggestive of malignancy are identified in peritoneal washing specimens when a corresponding benign or discordantly low grade malignant diagnosis is made in the surgical pathology specimen. We present two such cases in which further investigation proved extremely valuable, not only leading to resolution of initially discrepant cytologic and surgical pathology findings but also in the process leading to second diagnoses of early fallopian tube carcinoma. Increasing evidence appears to be pointing to the fallopian tube as the site of origin of many serous carcinomas previously thought to be of primary pelvic or ovarian origin. These cases further confirm the utility of peritoneal washing cytology as a diagnostic modality when routine gross examination and sampling of the surgical specimens alone would have failed to provide the complete diagnosis."
2010 surgical oncology: Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
"Experience with lymph node involvement (LNI) in ovarian serous tumors of low malignant potential (OSLMP) is limited, which has led to an uncertainty about the clinical significance of this phenomenon....."
the actual program itinerary and related abstracts:
Note: several years ago Cary Vera Garcia (deceased) published an article about ovarian cancer as a chronic disease. It was an excellent article and she felt using the term chronic as it may apply to ovarian cancer 'Devalued a Survivor's Challenge'. Dr Markman wrote a response concerning the clinical use of the word 'chronic' as it may apply to ovarian cancer. So, 'very serious chronic' is a new term which is interesting.
Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S40-3.
Optimal management of recurrent ovarian cancer.
Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. email@example.com
The development of an optimal management approach in recurrent ovarian cancer requires careful consideration of a number of important factors including (a) response to and severity/persistence of toxicity associated with prior therapy, (b) existence of relevant trial data (particularly phase 3 studies), (c) patient interest in participating in clinical trials, (d) cost of (and ability to pay for) particular anti-neoplastic drug regimens, and (e) patient choice. It is likely that the increasing availability of biologically active novel agents (and combination programs) in this clinical setting will add to the difficulty of defining optimal therapy in recurrent/resistant ovarian cancer, which, in many individuals, can be reasonably considered a very serious chronic disease process.
abstract: Symptom control pts with recurrent OC: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistan
Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antia
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Friday, January 08, 2010
Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives - Annual Review of Medicine, 61(1):301 - Abstract
"While public health policies aimed at curbing the underlying causes of the obesity epidemic are being implemented, there is a parallel need to better understand the biological processes linking obesity and cancer as a prerequisite to the development of new approaches to prevention and treatment."
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies* - Annual Review of Medicine, 61(1):35 - Abstract
Laboratory of Molecular Medicine and Neuroscience, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892; email: firstname.lastname@example.org
"Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the white matter of the human brain caused by lytic infection of oligodendrocytes with the human polyomavirus JCV. Although the majority of PML cases occur in severely immune-suppressed individuals, with HIV-1 infection as the predominant factor, PML has been increasingly diagnosed in patients treated with biological therapies such as monoclonal antibodies that modulate immune system functions...."
full free access
Some interesting observations in this article including:
"Per capita, Canada has one third fewer active physicians than the United States, 15% more primary care physicians, and half as many specialists. Consequently, the heavy responsibilities of Canadian specialists promote shared care with family physicians, and specialists rarely see patients without referral. In the United States, only 30% of visits to specialists occur through referrals,5 and patients are likely to see multiple specialists."
New Concepts in Organ Site Research:
Recent Advances in Ovarian Cancer Research
Co-Chairpersons: Christopher P. Crum, Brigham and Women's Hospital, Boston, MA, and Shelley S. Tworoger, Brigham and Women's Hospital, Boston, MA
* David D. Bowtell, Peter MacCallum Cancer Center, Melbourne, Australia
* Elise C. Kohn, National Cancer Institute, Bethesda, MD
* Martin Widschwendter, Institute for Women's Health, University College London, London, United Kingdom
* Alicja Wolk, National Institute of Environmental Medicine, Stockholm, Sweden
January 8th, 2009:
We are now accepting applications for the Advocates Partnership Program at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, March 24-28 in Albuquerque, New Mexico.
The Advocates Partnership Program aims to foster new connections among members of the genetics community. Highlights for participants include engaging in thought-provoking discussions about clinical genetics and informatics, and attending exclusive daily briefings with ACMG staff and professionals working in your area of interest. The ACMG preliminary meeting schedule is available at http://www.acmgmeeting.net/schedule.php
Acceptance into the Advocates Partnership Program includes waived full registration to the ACMG Annual Clinical Genetics Meeting. Furthermore, participants will be reimbursed for up to $250 for transportation, hotel accommodations, or airfare.
We welcome applications from individuals interested in the field of clinical genetics. Individuals who hold ACMG membership or those who could be a potential candidate for membership are not eligible to apply for the Advocates Partnership Program.
To apply, please download the application form from http://www.geneticalliance.org/advocates.opportunities.
Please return it to email@example.com no later than Friday, February 5, 2010.
Priority will be given to individuals who previously have not participated in the Advocates Partnership Program.
Please forward this message to your friends and colleagues.
If you have any questions, please contact Tetyana Murza at firstname.lastname@example.org or (202) 966-5557 ext. 205. We look forward to hearing from you.
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
Jan 7th, 2009 abstract and full free access
Thursday, January 07, 2010
preclinical studies to come in 2010
full free access-focus on Lynch Syndrome Ultradeep Sequencing of a Human Ultraconserved Region Reveals Somatic and Constitutional Genomic Instability
"Genomic instability is a common trait of cancer cells and plays a pivotal role in promoting carcinogenesis in several hereditary tumours. One of the best-known examples is the Lynch syndrome, an autosomal dominant condition associated with heterozygous mutations in mismatch repair (MMR) genes. During their lifespan, individuals affected by the Lynch syndrome...... The tumourigenic process starts when mutations hit oncogenes and/or tumour suppressors, often in actively renovating tissues such as endometrium, ovary, and colon. In the latter case, the genetic condition is known as hereditary non-polyposis colorectal cancer (HNPCC), which represents the most common form of inherited colorectal cancer.... Since more than 90% of HNPCC show MSI this has become a common diagnostic marker..."
See also Table 1:Occult Influences of the Clinical Trial Setting on the Generalizability of Results - Differences in the Patient Population
"As clinical trials increasingly become a global enterprise, issues of generalizability will increase in importance. It will be essential to ensure that the conduct of a trial and its subsequent reporting include attention to aspects that influence generalizability, so that determinations of whether observations and conclusions reached in one geographic setting, or within one type of health care system, are applicable to the policy makers and practitioners from other settings."
JCO Editorial: Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?
"Thus, these candidate biomarkers should continue to be actively explored in trials of antiangiogenic agents in patients, to get closer to the goal of improving and individualizing cancer therapy."
full free access - click on the 'pdf' box - top right corner
There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming From Arrayit Corporation, and It Will Be Available Soon - OvaDx(TM)
Note: The test will soon be submitted to the FDA for approval
BJC - Abstract: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Note: ovarian cancer patients were included in this phase 1 study but abstract gives limited information
Note: As far as I can tell this test still needs approvals
Ovanome is a genetic test for predicting an ovarian cancer patient’s response to first-regimen Taxol¹ and carboplatin (TC) chemotherapy. 30% of chemo-naive women do not respond to TC treatment and DNAPrint™ research shows that this problem is largely a function of genetic polymorphism.
Biotech News & Online Store - Belinostat phase II trial initiated in platinum-resistant ovarian cancer by the Gynecologic Oncology Group (GOG) supported by
A Phase II evaluation of Belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
Our ‘i LEARN – u LEARN’ events are taking place in March 2010.
These are six interactive meetings that will be held in
* London (1 & 17 March 2010)
* Belfast (4 March 2010)
* Cardiff (9 March 2010)
* Liverpool (12 March 2010)
* Edinburgh (15 March 2010)
At these meetings, you can find out more about regulation in the health sector and take part in various activities where you can lend your voice to some ongoing debates. We will be supported at all meetings by representatives from the health professional regulatory bodies. Places at these meetings are limited, so we encourage you to register early to attend these events. You can register by emailing us at email@example.com or by calling us on 020 7389 8030.
Wednesday, January 06, 2010
Study: Ginkgo biloba has no effect on Alzheimer's, dementia
Note: below the abstract click on 'pdf download article' (full free access)
"This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials."
full free access (2008) Prevention of Venous Thromboembolism* — CHEST gynecologic cancers are included
This is a very long article, includes gynecologic cancer surgery as well as other topics regarding blood clots including for at-risk travellers:
"Cancer patients undergoing surgery have at least twice the risk of postoperative DVT and more than three times the risk of fatal PE encountered by noncancer patients who are undergoing similar procedures."
press release: Vermillion Unsecured Creditors Approve Proposed Plan of Reorganization -- FREMONT, Calif., Jan. 6 /PRNewswire-FirstCall/ --
About the OVA1 Test
The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) --- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
OVA1(TM) Test is a trademark of Vermillion Inc.
full free access: TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use — Cold Spring Harbor Perspectives in Biology
Somatic TP53 mutations occur in almost every type of cancer at rates from 38%–50% in ovarian and..........TP53 mutations, but not p53 positive immunohistochemistry (IHC), have been consistently associated with poor prognosis in cancers such as breast, colorectal, head and neck, and leukemia.....In terms of clinical applications, TP53 mutations have proven to be extremely complex biomarkers. Despite impressive progress in mechanistic understanding of p53 structure and function, p53 research has not yet generated applications of wide impact on cancer management and therapy."
Tuesday, January 05, 2010
abstract/full text: Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel
"Clear cell carcinoma has been classified as a subgroup of EOC and reported to be an interesting histologic type with unique clinical features. CCC showed a poorer prognosis compared to serous adenocarcinoma because it tended to be resistant to antineoplastic agents, including paclitaxel.
CCC comprises more than 15% of EOC cases in Japan, although it represents 8–10% of all EOC cases in the USA. Therefore, it is important to establish new treatment strategies to improve the prognosis of CCC patients.
GPC3 regulates cell growth either positively or negatively depending on the cell type. Genetic and functional studies showed that glypicans regulate the signaling activity of various morphogens, including Wnts, Hedgehogs, bone morphogenic proteins, and fibroblast growth factors. Previous studies showed that GPC3 was overexpressed in Wilms' tumor, hepatocellular carcinoma, and hepatoblastoma. In ovarian carcinoma, GPC3 was overexpressed in yolk sac tumor and CCC.(15–17) However, GPC3 function in CCC was unclear. Furthermore, we investigated the role of this molecule in the sensitivity of CCC to paclitaxel, which is a key drug for ovarian cancer, using shRNA targeting GPC3.
Taken together, our data could support the use of GPC3-targeted therapies for CCC patients. We suggest that therapy targeting to GPC3 may be a novel treatment strategy that could potentially help to prevent the appearance, progression, and/or recurrence of CCC."
full free access:
Monday, January 04, 2010
Certain hereditary conditions, including:
New platinum compound shows promise in tumor cells
"The new compound, mitaplatin, combines cisplatin with another compound, dichloroacetate (DCA), which can alter the properties of mitochondria selectively in cancer cells. Cancer cells switch their mitochondrial properties to change the way they metabolize glucose compared to normal cells, and DCA specifically targets the altered mitochondria, leaving normal cells intact."
Sunday, January 03, 2010
Saturday, January 02, 2010
Note: at this moment the website shows that 1,770+ letters have been written, only 14 ovarian cancer contributions
(to check out the website click on the logo for further information)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer: A Panacea or Just an Obstacle Course for the Patient?
comment: although this discussion is related to colorectal cancer, awareness of these concerns is relevant to our community, I believe
"1- to 8-year age group had the highest percentage of malignancies"
Friday, January 01, 2010
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG ph 111
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
"For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."
includes prophylactic (preventative) surgery
"If chemotherapy is indicated, we recommend delaying administration, if possible, until after the delivery or at least after 20 weeks in order to minimize the potential fetal toxicity".
Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Note: It's unfortunate that early stages of ovarian cancers were not included in this study.
Thursday, December 31, 2009
"Ovarian disease (cancer) was diagnosed at a median of 5 years after breast cancer. Seventy-five percent of patients were asymptomatic, and advanced-stage pelvic extent or extra-abdominal metastases were observed in 41.5% of patients. The median survival was 3 years..."
"...A, E, D can cause serious adverse events."
CONCLUSIONS: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.
we do not have a proven biomarker, panel of biomarkers, or overall screening program that works well. The current report, with its sobering implications, brings us closer to understanding the crucial elements in designing any effective early detection program for ovarian cancer...."
free full access: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- JNCI
Note: small study, did not include family history of colorectal cancer (Lynch Syndrome); clear cell ovarian subtype
THE RESEARCH ARTICLE:
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al., 10.1093/jnci/djp438 -- JNCI Journal of the National Cancer Institute
Wednesday, December 30, 2009
Assessing lead time of selected ovarian cancer biomarkers
"Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis. The stage of the cancer at the time of marker elevation is not known.
CA125, HE4, mesothelin, B7-H4, decoy receptor 3, and spondin-2 have been identified as potential ovarian cancer biomarkers, but their behavior in the pre-diagnostic period, with the exception of CA125, has not been evaluated previously."
Tuesday, December 29, 2009
Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells
Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells
O bituaries routinely inform us that so-and-so has died "after a brave battle against cancer".
Of course, we will never read that so-and-so has died "after a pathetically feeble battle against cancer".
Wednesday, December 23, 2009 E-health revolution; Island doctors and nurses first in B.C. to have instant access to patients' histories
Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors
Forty-five women (73%) had ovarian cancer, 10 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papillary serous tumors.